Skip to main content
. 2019 Mar 28;125(14):2474–2487. doi: 10.1002/cncr.32116

Figure 6.

Figure 6

OS censored at the time of blinatumomab, a tyrosine kinase inhibitor, chimeric antigen receptor T‐cell therapy, or InO. †One‐sided log‐rank test. CI indicates confidence interval; HR, hazard ratio; InO, inotuzumab ozogamicin; OS, overall survival; SoC, standard of care (intensive chemotherapy).